Balyasny Asset Management L.P. reduced its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 81.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 69,586 shares of the company's stock after selling 297,591 shares during the period. Balyasny Asset Management L.P. owned 0.08% of Syndax Pharmaceuticals worth $920,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in SNDX. R Squared Ltd acquired a new stake in shares of Syndax Pharmaceuticals in the 4th quarter worth approximately $26,000. Virtus ETF Advisers LLC raised its position in shares of Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after buying an additional 827 shares during the period. Cape Investment Advisory Inc. raised its position in shares of Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock worth $85,000 after buying an additional 3,927 shares during the period. KBC Group NV raised its position in shares of Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after buying an additional 3,559 shares during the period. Finally, Optimize Financial Inc purchased a new position in shares of Syndax Pharmaceuticals in the 4th quarter worth $152,000.
Syndax Pharmaceuticals Stock Performance
Shares of SNDX traded up $1.01 during mid-day trading on Tuesday, reaching $10.31. 700,541 shares of the company's stock traded hands, compared to its average volume of 1,726,169. The business's 50-day moving average price is $12.02 and its 200-day moving average price is $13.97. The stock has a market capitalization of $887.14 million, a P/E ratio of -2.84 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $25.07.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. Syndax Pharmaceuticals's revenue for the quarter was up 1900.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.85) EPS. Equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.
Analysts Set New Price Targets
SNDX has been the topic of several research reports. Guggenheim reaffirmed a "buy" rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. StockNews.com raised Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. Citigroup lowered their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, Scotiabank lifted their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $35.91.
View Our Latest Stock Analysis on SNDX
About Syndax Pharmaceuticals
(
Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Recommended Stories
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
